Form 4 for BIAF bioAffinity Technologies, Inc.
Accepted 2025-01-14 00:00:00 ET · period of report 2025-01-10 · accession 0001493152-25-002150 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-14 | 2025-01-10 | BIAF | Zannes Maria | Pres, CEO, Dir | A - Grant | $0.00 | +37.0K | 280.4K | +15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-10 | A | A | 37,037 | $0.00 | 280,359 | D | — | — | (F1) Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025. |